Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2009
11/26/2009WO2009140722A1 A modified galectin-2 and uses thereof
11/26/2009WO2009125071A3 Extract with high amount of quebrachitol and its use
11/26/2009WO2009120300A3 Method of treating degenerative diseases
11/26/2009WO2009120039A3 Use of cd9 for a target protein to develop anticancer drug of solid cancers that overexpress cd9
11/26/2009WO2009118771A3 Use of lactoferrin for prevention of neonatal sepses in premature newborns
11/26/2009WO2009116836A3 Agent comprising g-csf for treatment of traumatic peripheral nerve injury and method for treating traumatic peripheral nerve injury with the same
11/26/2009WO2009116764A3 Cell migration, cell infiltration, or neovascularization inhibitor through degradation of function of ptk7 protein
11/26/2009WO2009115664A3 Crystalline structure of the cc2-lz domain of nemo
11/26/2009WO2009115331A3 Protein product for modifying cardiovascular health
11/26/2009WO2009114520A3 Compositions for treatment with metallopeptidases, methods of making and using the same
11/26/2009WO2009108868A3 Radiolabeled hedgehog derivatives for imaging and therapy
11/26/2009WO2009108716A3 Synthetic peptides
11/26/2009WO2009105629A3 Methods for the treatment and prevention of necrotizing enterocolitis
11/26/2009WO2009101199A3 Treatment of acne vulgaris; rosacea and rhinophym
11/26/2009WO2009095916A3 Cd14 and peptides thereof for protection of cells against cell death
11/26/2009WO2009093246A3 Clusterin derived peptide
11/26/2009WO2009093119A3 Use of serine protease inhibitors in the treatment of skin diseases
11/26/2009WO2009080699A3 Peg-interferon-beta formulations
11/26/2009WO2009056833A3 Composition
11/26/2009WO2009043458A3 Use of oxytocin to treat many diseases
11/26/2009WO2009043457A3 Use of human hemokinin-1 and optionally oxytocin to treat diseases involving excessive angiogenesis
11/26/2009WO2009040024A3 Use of bim-23127 and optionally urodilatin as therapeutic agents eg for the treatment of m. tuberculosis infections
11/26/2009WO2009039981A3 Use of (arg 8) vasopressin to treat eg s. pneumoniae infection
11/26/2009WO2009039980A3 Use of bfgf 1-24 and optionally (arg 8) vasopressin to treat eg s. pneumoniae infection
11/26/2009WO2009033820A3 Use of saralasin and carbetocin in combination to treat of eg aids or idiopathic pulmonary fibrosis
11/26/2009WO2009033783A3 Use of carbetocin to treat of eg aids or idiopathic pulmonary fibrosis
11/26/2009WO2009033782A3 Use of a teprotide and optionally carbetocin to treat eg aids or idiopathic pulmonay fibrosis
11/26/2009WO2009023601A3 Apparatus and methods for treating epilepsy using convection-enhanced delivery
11/26/2009WO2008113145A8 Proteins from the webs of nephilengys cruentata, avicularia juruensis and parawixia bistriata spiders
11/26/2009WO2008089466A3 Fibrin gel for controlled release of tgf-beta and uses thereof
11/26/2009WO2006009674A8 Macrocyclic modulators of the ghrelin receptor
11/26/2009WO2006009645A8 Methods of using macrocyclic modulators of the ghrelin receptor
11/26/2009US20090292113 Recombinant soluble Fc receptors
11/26/2009US20090292112 provide polypeptides inter alia that have been identified as novel proteins with homology to the Mindin family of extracellular matrix proteins (RG1); prostate cancer or benign prostatic hyperplasia, which is alleviated by decreasing the level of RG1 activity
11/26/2009US20090292107 Composition and method to alter lean body mass and bone properties in a subject
11/26/2009US20090292007 Inhibition of TACE or amphiregulin for the Modulation of EGF Receptor Signal Transactivation
11/26/2009US20090291998 Eponemycin and epoxomicin analogs and uses thereof
11/26/2009US20090291903 Substituted pyrrolidine amides as modulators of the histamine h3 receptor
11/26/2009US20090291902 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
11/26/2009US20090291901 Control of radiation injury
11/26/2009US20090291900 Methods for treatment of headaches by administration of oxytocin
11/26/2009US20090291899 Selective Modulation of Receptor Signalling
11/26/2009US20090291898 Novel anti-microbial peptidomimetic compounds and methods to calculate anti-microbial activity
11/26/2009US20090291897 Methods for treating unwanted weight loss or eating disorders by administering a trkb agonist
11/26/2009US20090291895 Methods and Compositions for the Treatment of Inflammatory Diseases
11/26/2009US20090291894 Methods for treating progressive cognitive disorders related to neurofibrillary tangles
11/26/2009US20090291893 Compositions for the prevention and treatment of neuroinjury and methods of use thereof
11/26/2009US20090291892 SlpA as a tool for recombinant protein and enzyme technology
11/26/2009US20090291891 VEGF variant that lacks VEGFR-1 binding activity and its use in promotion of re-endothelization and prevention of in-stent restenosis
11/26/2009US20090291890 Factor VII polypeptides that are modified and uses thereof
11/26/2009US20090291889 Diagnostic assay and method of treatment for miscarriage risk or premature birth involving macrophage inhibitory cytokine-1 (MIC-1)
11/26/2009US20090291888 Modulators of tnf receptor associated factor (traf), their preparation and use
11/26/2009US20090291887 Proteins of the SDF-1-Family for the Manufacturing of a Medicament
11/26/2009US20090291886 Transmucosal delivery of peptides and proteins
11/26/2009US20090291885 Conjugated toxin peptide therapeutic agents
11/26/2009US20090291884 Proteins for use in diagnosing and treating infection and disease
11/26/2009US20090291883 Combination of an immunosuppressive agent and nonsteroidal anti -inflammatory drugs to treat disease
11/26/2009US20090291882 Coatings for drug delivery devices
11/26/2009US20090291881 Coatings for drug delivery devices
11/26/2009US20090291880 Methods comprising desmopressin
11/26/2009US20090291879 Modulation of cartilage homeostasis by active domains of cell binding extracelular matrix molecules
11/26/2009US20090291878 Modulators of protein phosphatase 2a holoenyme
11/26/2009US20090291877 Treatments using citrulline
11/26/2009US20090291450 Caterpiller gene family
11/26/2009US20090291153 Health food, Method for producing the same and dried Product and Extract
11/26/2009US20090291144 Therapeutic and Prophylactic Compositions Including Catalytic Biomimetic Solids and Methods to Prepare and Use Them
11/26/2009US20090291139 Sparc and methods of use thereof
11/26/2009US20090291130 Physiologically Active Polypeptide- or Protein-Encapsulating Polymer Micelles, and Method for Production of the Same
11/26/2009US20090291124 Functional Nano-Layered Hemostatic Material/Device
11/26/2009US20090291122 Wound Care Treatment Product
11/26/2009US20090291114 Osteogenic composition comprising a growth factor/amphiphilic polymer complex, a soluble cation salt and an organic support
11/26/2009US20090291113 Osteogenic composition comprising a growth factor, a soluble cation salt and organic support
11/26/2009US20090291112 Allograft osteochondral plug combined with cartilage particle mixture
11/26/2009US20090291104 Novel conotoxin framework with a helix-loop-helix fold
11/26/2009US20090291100 Therapeutic agent for polycystic ovary syndrome (pcos)
11/26/2009US20090291098 Immunogenic LHRH compositions and methods relating thereto
11/26/2009US20090291097 IL-17 homologous polypeptides and therapeutic uses thereof
11/26/2009US20090291092 Treatment of mitochondrial diseases with an erythropoietin mimetic
11/26/2009US20090291091 Use of the globular domain of acrp30 for the preparation of a medicament for the prevention and/or treatment of thrombosis-related diseases
11/26/2009US20090291086 Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia
11/26/2009US20090291073 Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
11/26/2009US20090291070 Biologically Active Silver-Coated Proteins
11/26/2009US20090291066 composition and method of treating facial skin defect
11/26/2009US20090291062 Protein formulations and methods of making same
11/26/2009US20090291061 Stem cell therapy for blood vessel degeneration
11/26/2009US20090291060 Treatment of HIV
11/26/2009US20090291049 Targeted delivery to human diseases and disorders
11/26/2009US20090291047 Therapy with clostridium perfringens enterotoxin to treat ovarian and uterine cancer
11/26/2009DE10234192B4 Verwendung von Erythropoetin Use of erythropoietin
11/26/2009DE102008025008A1 Insulin analogs which comprise A chain and B chain with disulfide bonds for use in treatment of diabetes
11/26/2009DE102008025007A1 Insulin analogs which comprise A chain and B chain with disulfide bonds for use in treatment of diabetes and for cartilage regeneration
11/26/2009CA2725527A1 The large form of human 2',5'-oligoadenylate synthetase oas3 for preventing or treating infection with positive-sense single-stranded rna viruses
11/26/2009CA2725513A1 Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer
11/26/2009CA2725278A1 Depsipeptides and their therapeutic use
11/26/2009CA2725198A1 Novel soluble cd83 polypeptides, formulations and methods of use
11/26/2009CA2725154A1 Methods of treatment utilizing binding proteins of the interleukin-21 receptor
11/26/2009CA2725143A1 Methods for treating progressive cognitive disorders related to neurofibrillary tangles
11/26/2009CA2724982A1 Histamine binding protein
11/26/2009CA2724841A1 Treatment of mitochondrial diseases with an erythropoietin mimetic
11/26/2009CA2724830A1 Inhibition of the nt-3:trkc bound and its application to the treatment of cancer such as neuroblastoma
1 ... 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 ... 3163